HBM Healthcare Investments (Cayman) Ltd. disclosed a 12.5% stake in Chemomab Therapeutics Ltd. through American Depositary Shares and pre-funded warrants. On Jul. 16, 2026, the fund filed a Schedule 13D after steps that allow it to acquire all warrant shares within 60 days. The move supports a planned merger with Scipher Medicine and strengthens HBM’s voting power.
Investor Intent
HBM signed a Shareholder Support Agreement to vote all of its shares in favor of Chemomab’s merger with Scipher and against any competing proposal. It also agreed not to transfer its covered shares during the agreement’s term, citing a commitment to see the deal through.
To ensure full voting power, HBM consented to waive the prior 9.99% blocker cap on its pre‑funded warrants and notified Chemomab it will raise the blocker to 19.99% effective Sep. 7, 2026. HBM plans to exercise its pre‑funded warrants on a cashless basis after that date to meet its voting obligations. Key quotes: “vote all of its Ordinary Shares … in favor of the Merger Agreement” and “not to transfer any of its Covered Shares.”
Investor's Background
HBM Healthcare Investments (Cayman) Ltd. is an offshore venture capital entity focused on acquiring, holding, and selling interests in emerging growth companies. The firm specializes in healthcare and biotechnology and often backs clinical-stage innovators. HBM’s strategy centers on concentrated, long-term positions and active engagement around key corporate events.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.